Neurotrope, Inc

(NASDAQ:NTRP)

Latest On Neurotrope, Inc (NTRP):

Date/Time Type Description Signal Details
2020-12-07 00:17 ESTFinancialsCompany financials have been released.Neutral
2020-12-03 04:22 ESTNewsNeurotrope, Metuchen Pharmaceuticals merge to form new public companyN/A
2020-11-26 21:01 ESTFinancialsCompany financials have been released.Neutral
2020-11-21 01:37 ESTNewsNeurotrope approves spin-off of Neurotrope Bioscience; announces distribution dateN/A
2020-11-12 12:34 ESTFinancialsCompany financials have been released.Neutral
2020-11-08 00:22 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 16:39 ESTFinancialsCompany financials have been released.Neutral
2020-11-02 09:42 ESTInsider TradeJONATHAN SCHECHTER has directly acquired 25,000 shares and currently holds 75,000 shares.Buy
2020-10-26 09:41 ESTInsider TradeJONATHAN SCHECHTER has directly acquired 25,000 shares and currently holds 50,000 shares.Buy
2020-10-22 09:42 ESTInsider TradeJONATHAN SCHECHTER has directly acquired 22,988 shares and currently holds 25,000 shares.Buy
2020-10-22 09:42 ESTInsider TradeJONATHAN SCHECHTER has directly acquired 2,012 shares and currently holds 2,012 shares.Buy
2020-10-20 09:46 ESTInsider TradeJoshua Silverman has directly acquired 50,000 shares and currently holds 100,000 shares.Buy
2020-10-19 09:14 ESTInsider TradeJoshua Silverman has directly acquired 50,000 shares and currently holds 50,000 shares.Buy
2020-10-06 18:33 ESTNewsNeurotrope initiates long-term Alzheimer's study with bryostatinN/A
2020-09-26 13:34 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 05:40 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 09:38 ESTFinancialsCompany financials have been released.Neutral
2020-08-13 05:28 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 13:24 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 01:51 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 17:20 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 05:19 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 13:16 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 17:55 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 09:31 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 17:19 ESTFinancialsCompany financials have been released.Neutral
2020-06-26 09:31 ESTFinancialsCompany financials have been released.Neutral
2020-06-17 05:21 ESTFinancialsCompany financials have been released.Neutral
2020-06-14 05:14 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 05:36 ESTFinancialsCompany financials have been released.Neutral
2020-06-11 14:56 ESTNewsNeurotrope secures supply of Bryostatin-1N/A
2020-05-27 05:43 ESTFinancialsCompany financials have been released.Neutral
2020-05-06 05:48 ESTFinancialsCompany financials have been released.Neutral
2020-05-01 05:19 ESTFinancialsCompany financials have been released.Neutral
2020-04-19 14:13 ESTNewsNeurotrope files for $100M mixed shelfN/A
2020-04-03 21:18 ESTFinancialsCompany financials have been released.Neutral
2020-03-15 21:07 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 04:34 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 04:34 ESTEarningsEarnings have been released on March 12, 2019, with -$0.45 earnings per share.Sell
2020-02-28 04:34 ESTEarningsEarnings have been released on March 1, 2017, with -$0.51 earnings per share.Buy
2020-02-27 21:50 ESTFinancialsCompany financials have been released.Neutral
2020-02-22 00:18 ESTFinancialsCompany financials have been released.Neutral
2020-02-13 00:19 ESTFinancialsCompany financials have been released.Neutral
2020-02-07 00:25 ESTFinancialsCompany financials have been released.Neutral
2020-02-03 11:16 ESTNewsBiogen And Neurotrope: Why Numbers Cannot Overcome Alzheimer's DiseaseN/A
2020-02-01 00:20 ESTFinancialsCompany financials have been released.Neutral
2020-01-29 00:16 ESTFinancialsCompany financials have been released.Neutral
2020-01-28 04:36 ESTEarningsEarnings have been released on November 27, 2019, with -$0.29 earnings per share.Buy
2020-01-28 04:36 ESTEarningsEarnings have been released on November 29, 2017, with -$0.29 earnings per share.Buy
2020-01-28 00:22 ESTFinancialsCompany financials have been released.Neutral

About Neurotrope, Inc (NTRP):

Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.

NTRP Quotes by TradingView

See Advanced Chart

General

  • Name Neurotrope, Inc
  • Symbol NTRP
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 5
  • Last Split Factor1:32
  • Last Split Date2017-01-12
  • Fiscal Year EndDecember
  • IPO Date2013-10-02
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://neurotrope.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 0.8
  • Enterprise Value EBITDA 0.42
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Return on Assets -28%
  • Earnings Per Share -$1.48
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 22.39 million
  • EBITDA -15887709
  • Analyst Target Price $1
  • Book Value Per Share $1.17
View More

Share Statistics

  • Shares Outstanding 23.79 million
  • Shares Float 20.08 million
  • % Held by Insiders 1225%
  • % Held by Institutions 9.17%
  • Shares Short 46336
  • Shares Short Prior Month 189206
  • Short Ratio 0.19
View More

Technicals

  • Beta 2.26
  • 52 Week High $1.55
  • 52 Week Low $0.68
  • 50 Day Moving Average 0.99
  • 200 Day Moving Average 1.14
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Neurotrope, Inc (NTRP) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Neurotrope, Inc (NTRP) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-10$N/A-$0.18
2020-06-302020-08-06$N/A-$0.13
2020-03-312020-06-12$N/A-$0.14
2019-12-312020-03-13$N/A-$0.20
2019-09-302019-11-12$N/A-$0.29-$0.329.38%
2019-06-302019-08-08$N/A-$0.31-$0.336.06%
2019-03-312019-05-09$N/A-$0.36-$0.28-28.57%
2018-12-312019-03-08$N/A-$0.44-$0.37-18.92%
2018-09-302018-10-30$N/A-$0.40-$0.4511.11%
2018-06-302018-08-10$N/A-$0.27-$0.4235.71%
2018-03-312018-05-14$N/A-$0.25-$0.3119.35%
2017-12-312018-03-06$N/A-$0.55
2017-09-302017-11-03$N/A-$0.29-$0.4332.56%
2017-06-302017-08-08$N/A-$0.38-$0.4515.56%
2017-03-312017-05-12$N/A-$0.43-$0.6028.33%
2016-12-312017-03-10$N/A-$0.51-$0.6014.28%
2016-09-302016-11-14$N/A-$2.64
2016-06-302016-08-15$N/A-$1.75
2016-03-312016-05-13$N/A-$1.72
2015-12-312016-03-07$N/A-$1.92
2015-09-302015-11-13$N/A-$2.56
2015-06-302015-08-14$N/A-$3.46
2015-03-312015-05-14$N/A-$6.54
2014-12-312014-12-31$N/A-$3.19
2014-09-302014-09-30$N/A-$4.58
2014-06-302014-06-30$N/A-$2.96
2014-03-312014-03-31$N/A-$2.47
2013-12-312013-12-31$N/A-$2.56

Neurotrope, Inc (NTRP) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Neurotrope, Inc (NTRP) Chart:

Neurotrope, Inc (NTRP) News:

Below you will find a list of latest news for Neurotrope, Inc (NTRP) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Neurotrope, Inc (NTRP) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Neurotrope, Inc (NTRP) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1513856/000110465920072970/0001104659-20-072970-index.htm
2020-04-22UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1513856/000000000020003451/0000000000-20-003451-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1513856/000093041320000370/0000930413-20-000370-index.htm
2019-10-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000110465919056571/0001104659-19-056571-index.htm
2019-10-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000110465919056572/0001104659-19-056572-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1513856/000110465919062005/0001104659-19-062005-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513856/000110465919073078/0001104659-19-073078-index.htm
2020-01-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000110465920005340/0001104659-20-005340-index.htm
2020-01-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000110465920005734/0001104659-20-005734-index.htm
2020-01-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000110465920006109/0001104659-20-006109-index.htm
2020-01-23424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1513856/000110465920006110/0001104659-20-006110-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920018658/0001104659-20-018658-index.htm
2020-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000110465920025079/0001104659-20-025079-index.htm
2020-02-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000110465920026258/0001104659-20-026258-index.htm
2020-03-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1513856/000110465920033198/0001104659-20-033198-index.htm
2020-03-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920037863/0001104659-20-037863-index.htm
2020-03-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920037864/0001104659-20-037864-index.htm
2020-03-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920037865/0001104659-20-037865-index.htm
2020-03-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920037866/0001104659-20-037866-index.htm
2020-03-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920037867/0001104659-20-037867-index.htm
2020-03-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920037868/0001104659-20-037868-index.htm
2020-04-17S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1513856/000110465920048259/0001104659-20-048259-index.htm
2020-04-22CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1513856/000110465920049672/0001104659-20-049672-index.htm
2020-04-24424B2Prospectus [Rule 424(b)(2)]https://www.sec.gov/Archives/edgar/data/1513856/000110465920051073/0001104659-20-051073-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000110465920059622/0001104659-20-059622-index.htm
2020-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000110465920062969/0001104659-20-062969-index.htm
2020-05-18425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920062970/0001104659-20-062970-index.htm
2020-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000110465920067147/0001104659-20-067147-index.htm
2020-05-28425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920067148/0001104659-20-067148-index.htm
2020-06-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1513856/000110465920072970/0001104659-20-072970-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000110465920086081/0001104659-20-086081-index.htm
2020-07-24425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920086082/0001104659-20-086082-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000110465920086515/0001104659-20-086515-index.htm
2020-07-24425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920086516/0001104659-20-086516-index.htm
2020-07-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000110465920087851/0001104659-20-087851-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1513856/000110465920092817/0001104659-20-092817-index.htm
2020-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000110465920110208/0001104659-20-110208-index.htm
2020-09-30425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920110209/0001104659-20-110209-index.htm
2020-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000110465920110217/0001104659-20-110217-index.htm
2020-09-30425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920110220/0001104659-20-110220-index.htm
2020-10-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920115850/0001104659-20-115850-index.htm
2020-10-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920116286/0001104659-20-116286-index.htm
2020-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920117012/0001104659-20-117012-index.htm
2020-10-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920118010/0001104659-20-118010-index.htm
2020-11-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1513856/000110465920120279/0001104659-20-120279-index.htm
2020-11-02DEFM14ADefinitive proxy statement relating to merger or acquisitionhttps://www.sec.gov/Archives/edgar/data/1513856/000110465920120571/0001104659-20-120571-index.htm
2019-06-05DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1513856/000114420419029814/0001144204-19-029814-index.htm
2019-06-05DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1513856/000114420419029816/0001144204-19-029816-index.htm
2019-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000114420419035754/0001144204-19-035754-index.htm
2019-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000114420419037635/0001144204-19-037635-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1513856/000114420419038612/0001144204-19-038612-index.htm
2019-08-26S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1513856/000114420419041678/0001144204-19-041678-index.htm
2019-08-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1513856/000114420419043026/0001144204-19-043026-index.htm
2019-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000114420419043867/0001144204-19-043867-index.htm
2019-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1513856/000114420419043868/0001144204-19-043868-index.htm
2019-09-098-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1513856/000114420419043870/0001144204-19-043870-index.htm
2020-01-31SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1513856/000121390020002194/0001213900-20-002194-index.htm
2020-04-24EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1513856/999999999520000859/9999999995-20-000859-index.htm

Neurotrope, Inc (NTRP) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Neurotrope, Inc (NTRP). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1225%
Institutional Ownership: 917%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-10-16Joshua SilvermanDirectorBuy50,000.001.0954,445.00100,000.00https://www.sec.gov/Archives/edgar/data/1513856/000110465920116286/0001104659-20-116286-index.htm
2020-10-20JONATHAN SCHECHTERDirectorBuy2,012.001.102,213.202,012.00https://www.sec.gov/Archives/edgar/data/1513856/000110465920117012/0001104659-20-117012-index.htm
2020-10-21JONATHAN SCHECHTERDirectorBuy22,988.001.1025,286.8025,000.00https://www.sec.gov/Archives/edgar/data/1513856/000110465920117012/0001104659-20-117012-index.htm
2020-10-22JONATHAN SCHECHTERDirectorBuy25,000.001.1027,500.0050,000.00https://www.sec.gov/Archives/edgar/data/1513856/000110465920118010/0001104659-20-118010-index.htm
2020-10-15Joshua SilvermanDirectorBuy50,000.001.0753,315.0050,000.00https://www.sec.gov/Archives/edgar/data/1513856/000110465920115850/0001104659-20-115850-index.htm
2020-10-30JONATHAN SCHECHTERDirectorBuy25,000.000.9824,442.5075,000.00https://www.sec.gov/Archives/edgar/data/1513856/000110465920120279/0001104659-20-120279-index.htm